Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Breast Cancer
Phase NA
Enrollment 5000
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare, for the second reading of screening mammograms, the standard of care with an AI assisted scenario. The main questions it aims to answer are: * will the experimental pathway be non-inferior to the standard pathway? * will the experimental pathway be economically superior to the standard pathway? Participants will receive screening mammograms, as part of the breast cancer screening program. Researchers will compare the interpretation made by the second reader in the standard pathway with the AI assisted interpretation made by a different reader in the experimental pathway.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Crossover Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: MammoScreen — Diagnostic reading aid for breast cancer screening

Primary Outcomes

  • Recall rate (End of the inclusion period 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-09
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Therapixel
Principal Investigators:
  • Brigitte Seradour (PRINCIPAL_INVESTIGATOR) - Centre Régional de Coordination des Dépistages des Cancers (CRCDC) Région Sud PACA
Contact Information
Study Contact:
Brigitte Seradour
06 09 88 38 64
brigitteseradour@hotmail.fr
Patrice Heid
06 09 07 83 67
p.heid@depistage-cancerssud.org
Francoise LECRIVAIN
Centre de radiologie Les Défensions
Interventions
  • Device: MammoScreen — Diagnostic reading aid for breast cancer screening
Study Locations (7 sites)
Centre de radiologie Les Défensions, Aubagne, France
Var Imagerie Medicale, Draguignan, France
VAR IMAGERIE MEDICALE - Centre d'Imagerie Médicale Le Clipper, Fréjus, France
VAR IMAGERIE MEDICALE - Clinique Les Lauriers, Fréjus, France
Cabinet de Radiologie du Cabot, Marseille, France
Centre de Sénologie Mermoz, Marseille, France
VAR IMAGERIE MEDICALE - Centre d'Imagerie Médicale Epsilon, Saint-Raphaël, France
Eligibility Criteria
Inclusion Criteria: * Affiliated to the French social security system * Whose mammograms meet the following characteristics: 4 (2 per breast, CC and MLO) meeting local regulatory standards and with correct DICOM metadata, * Whose mammograms have been determined to be normal or to have benign lesions by the radiologist who performed the first reading of the images (L1) in the framework of the organized breast cancer screening program * Having expressed her willingness to participate in the study, to undergo all the procedures and to make herself available for the expected duration of their participation, * Having completed and signed the informed consent form. Exclusion Criteria: * Woman with breast implants, * With clinical symptoms of breast cancer, * With a history of breast surgery (breast reduction or surgery for benign lesion), * Pregnant or breastfeeding, * With medical conditions that may interfere with her ability to understand the requirements of the protocol or give informed consent, * Deprived of liberty by judicial or administrative order, * Participant whose mammogram images have at least one of the following defects: poor quality of the images, non-standard mammography (projection, magnification, compression), ML/LM/SIO/XCCL or XCCM view.
Conditions Breast Neoplasms
Phase PHASE2
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of neoadjuvant radiation therapy in improving local-regional control and facilitating surgical conversion in patients with inoperable locally advanced breast cancer after 2-6 courses of neoadjuvant chemotherapy. This study will also investigate whether beta-alanine supplementation and spatially fractionated radiotherapy can enhance the therapeutic response to neoadjuvant chemoradiotherapy. In addition, this study aims to explore tumor microenvironmental features and molecular biomarkers associated with treatment response, radioresistance, immune activation, and long-term outcomes.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Neoadjuvant radiotherapy — The preoperative radiation dose will be 50 Gy in 25 fractions to the breast and regional lymph node PTV, followed by surgical evaluation. Operable patients will proceed to surgery; inoperable patients will continue radiotherapy to 60 Gy in 30 fractions, with residual breast and nodal lesions boosted to 66 Gy in 33 fractions.
  • Dietary Supplement: β-alanine — β-alanine, 1.7g, tid, p.o
  • Radiation: Spatially fractionated radiotherapy — Spatially fractionated radiotherapy will be delivered as a lattice radiotherapy boost. The high-dose gross tumor volume (GTV) will receive 15 Gy in 1 fraction. The conventional clinical target volume (CTV), including the ipsilateral breast and regional lymphatic drainage area, will receive 40.05 Gy in 15 fractions. The boost volume, if applicable, including positive lymphatic drainage areas, will receive an additional 10 Gy in 5 fractions.

Primary Outcomes

  • Pathological response rate (1 year)
  • Fbjective response rate(ORR) (3 year)
  • Event free survival(EFS) (3 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-03-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Xiaoli Yu (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Xiaoli Yu
+86-021-64175590
xiaoliyu@fudan.edu.cn
Jin Meng
+86 18121299532
jinmeng@fudan.edu.cn
Xiaoli Yu
xiaoliyu@fudan.edu.cn
Fudan University Shanghai Cancer Center
Interventions
  • Radiation: Neoadjuvant radiotherapy — The preoperative radiation dose will be 50 Gy in 25 fractions to the breast and regional lymph node PTV, followed by surgical evaluation. Operable patients will proceed to surgery; inoperable patients will continue radiotherapy to 60 Gy in 30 fractions, with residual breast and nodal lesions boosted to 66 Gy in 33 fractions.
  • Dietary Supplement: β-alanine — β-alanine, 1.7g, tid, p.o
  • Radiation: Spatially fractionated radiotherapy — Spatially fractionated radiotherapy will be delivered as a lattice radiotherapy boost. The high-dose gross tumor volume (GTV) will receive 15 Gy in 1 fraction. The conventional clinical target volume (CTV), including the ipsilateral breast and regional lymphatic drainage area, will receive 40.05 Gy in 15 fractions. The boost volume, if applicable, including positive lymphatic drainage areas, will receive an additional 10 Gy in 5 fractions.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced breast carcinoma * Inoperable with with 4-6 courses of prior chemotherapy * No contradiction of radiation or chemo-radiotherapy * Patients should have the ability to understand and the willingness to sign a written informed consent document * Signed informed consent must be obtained prior to any study specific procedures Exclusion Criteria: * Other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or contralateral breast DCIS * Coagulation disorders * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia * Serious underlying medical illness with life expectancy less than 2 years. * Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
Conditions Breast Cancer Survivor, Cancer Related C...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The investigators are interested in finding out how Prolonged Nightly Fasting (PNF) and/or health education may impact health and cancer recovery for breast cancer patients and survivors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Prolonged Nightly Fasting — At the start of the intervention (week 1) PNF participants will be asked to engage in fasting (14 hours a night, starting no later than 8pm) six nights a week (for the 8-week study duration). Participants will be asked to track their fasting start/stop times on a tracking sheet provided by study staff. During the nightly fast, participants will be allowed to drink water, coffee or tea (without dairy or sweeteners). Study staff will meet with participants via phone for weekly check-in calls (\~10-15 mins) to collect weekly fasting start/stop dates/times (entered into REDCap); alternately, participants may elect to email or text their fasting start/stop date/times to the study staff.
  • Behavioral: Health Education Videos — Provision of HED is a retention strategy and can influence outcomes. Thus, all participants will receive HED. Each week, participants will receive hyperlinks to videos focused on health educational content unrelated to fasting, diet and outcome measures. Participants will be asked to view the videos (\~10-15 min) prior to their weekly check-in calls with the study staff (\~5-10 mins for HED-Only Control group). They will receive each week's videos on a Monday, and receive a reminder to view on Friday. Study staff will follow a scripted HED weekly check-in call to ensure consistency of data collected. Weekly topics are as follows: W1: Internet safety, W2: Sun safety, W3: Home safety, W4: Driving safety, W5: Hydration, W6: Dental health, W7: Working environment, W8: Communication. Data collected on electronic forms during all participant/staff check-in calls will be stored in participant-specific ASU Dropbox files.

Primary Outcomes

  • Examine PNF-induced changes in cognitive function as compared to the HED-Only control condition. (Baseline (T1) and 8-week end point (T2) data collection)
  • Examine PNF-induced changes in cognitive function as compared to the HED-Only control condition. (Baseline (T1) and 8-week end point (T2) data collection)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-18
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Arizona State University
Collaborators: Mayo Clinic
Principal Investigators:
  • Dorothy Sears, PhD (PRINCIPAL_INVESTIGATOR) - Arizona State University
  • Sarah James, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Jen Project Coordinator
602-496-8248
restorestudy@asu.edu
Dorothy Sears, PhD
602-496-3351
Dorothy.Sears@asu.edu
Jen Project Coordinator
602-496-8248
restorestudy@asu.edu
Arizona State University
Interventions
  • Behavioral: Prolonged Nightly Fasting — At the start of the intervention (week 1) PNF participants will be asked to engage in fasting (14 hours a night, starting no later than 8pm) six nights a week (for the 8-week study duration). Participants will be asked to track their fasting start/stop times on a tracking sheet provided by study staff. During the nightly fast, participants will be allowed to drink water, coffee or tea (without dairy or sweeteners). Study staff will meet with participants via phone for weekly check-in calls (\~10-15 mins) to collect weekly fasting start/stop dates/times (entered into REDCap); alternately, participants may elect to email or text their fasting start/stop date/times to the study staff.
  • Behavioral: Health Education Videos — Provision of HED is a retention strategy and can influence outcomes. Thus, all participants will receive HED. Each week, participants will receive hyperlinks to videos focused on health educational content unrelated to fasting, diet and outcome measures. Participants will be asked to view the videos (\~10-15 min) prior to their weekly check-in calls with the study staff (\~5-10 mins for HED-Only Control group). They will receive each week's videos on a Monday, and receive a reminder to view on Friday. Study staff will follow a scripted HED weekly check-in call to ensure consistency of data collected. Weekly topics are as follows: W1: Internet safety, W2: Sun safety, W3: Home safety, W4: Driving safety, W5: Hydration, W6: Dental health, W7: Working environment, W8: Communication. Data collected on electronic forms during all participant/staff check-in calls will be stored in participant-specific ASU Dropbox files.
Study Locations (1 sites)
Arizona State University, Phoenix, Arizona 85004 United States
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years old 2. diagnosed with breast cancer (all stages included) 3. ≥3 months post neoadjuvant or adjuvant chemotherapy (maintenance or palliative systemic therapy is included) 4. score ≤30 or lower on the Patient Reported Outcome Measurement Information System Cognitive Function Short Form 8a (sr-CRCI) 5. able to speak/understand English 6. have access to a computer and Wi-Fi 7. live within the United States 8. Identifies as female 9. willing and able to fully participate in the study Exclusion Criteria: 1. type 1 diabetes 2. actively enrolled in formal diet/weight loss program 3. previous bariatric surgery 4. eating disorder history 5. night shift work 6. pregnant, breast feeding, or trying to get pregnant 7. dementia, psychological, psychiatric, or neurological diagnoses 8. active brain or central nervous system disease 9. prior or current use of memory enhancing medications 10. history or current brain radiation 11. frequently fasting for 12+ hours every night 13\) history of hypoglycemia 14) depression screening on PHQ9 with a score of 20 or greater across all 9 questions OR anything other than 0 on question 9
Conditions Breast Cancer, Breast Reconstruction
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Study Design Prospective, single-center, observational, non-interventional study conducted in routine clinical practice. No investigational treatments or modifications to standard diagnostic, therapeutic, or follow-up procedures are planned. Consecutive eligible patients undergoing endoscopic nipple-sparing mastectomy (NSM) with immediate breast reconstruction will be prospectively enrolled. Background and Rationale Nipple-sparing mastectomy with immediate reconstruction is an established treatment for selected patients with breast cancer and women undergoing prophylactic mastectomy because of hereditary risk. Preservation of the nipple-areola complex (NAC) improves cosmetic outcomes, body image, and patient satisfaction while maintaining oncological safety. Endoscopic NSM is a minimally invasive alternative that may reduce scarring, surgical trauma, and recovery time while improving aesthetic outcomes without compromising oncological radicality. However, evidence remains limited, particularly in Europe, regarding feasibility, perioperative safety, sensory recovery, quality of life, reconstructive outcomes, and long-term oncological results. This study aims to prospectively collect real-world data from a consecutive cohort treated at a specialized breast center. Primary Objective To evaluate the feasibility and surgical safety of endoscopic NSM with immediate breast reconstruction in patients undergoing prophylactic or therapeutic mastectomy. Secondary Objectives To evaluate NAC sensory recovery at 6 and 12 months; assess oncological safety through surgical radicality and follow-up; evaluate quality of life and patient satisfaction using validated questionnaires; describe disease-free survival (DFS), overall survival (OS), reconstructive and aesthetic outcomes; and assess postoperative hospital stay. Primary Endpoints Overall incidence of early surgical complications; incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss; recovery of NAC sensation at 6 and 12 months; and pathological assessment of retroareolar margin status. Secondary Endpoints BREAST-Q scores; local, regional, and distant recurrence; DFS; OS; and reconstructive/aesthetic outcomes. Study Population and Sample Size Thirty consecutive adult women undergoing prophylactic or therapeutic NSM with immediate implant-based reconstruction according to multidisciplinary evaluation. Main Inclusion Criteria Female; age 18-75 years; indication for prophylactic or therapeutic NSM; breast volume suitable for endoscopic surgery; Regnault ptosis ≤ Grade II; eligibility for immediate implant-based reconstruction; WHO/ECOG performance status \<3; written informed consent. Main Exclusion Criteria Inflammatory breast cancer or skin involvement; previous breast cancer surgery or radiotherapy to the affected breast; BMI \>35 kg/m²; active smoking; ASA Physical Status \>2; pregnancy or breastfeeding; inability to provide…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: endoscopic mastectomy — Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow.

Primary Outcomes

  • Overall incidence of early surgical complications (adverse events in the first 90 days)
  • recovery of NAC sensation (6-12 months)
  • pathological assessment of retroareolar margin status (1 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-23
Completion: 2031-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massimiliano Bortolini
Contact Information
Study Contact:
Massimiliano Bortolini, MD
003901515156616
massimiliano.bortolini@aslbi.piemonte.it
Massimiliano Bortolini, MD
003901515156616
massimiliano.bortolini@aslbi.piemonte.it
Ospedale degli Infermi ASL BI
Interventions
  • Procedure: endoscopic mastectomy — Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow.
Study Locations (1 sites)
Ospedale degli Infermi ASL BI, Ponderano, BI 13875 Italy
Eligibility Criteria
Inclusion Criteria: * Female; age 18-75 years; * indication for prophylactic or therapeutic NSM; * breast volume suitable for endoscopic surgery; * Regnault ptosis ≤ Grade II; * eligibility for immediate implant-based reconstruction; * WHO/ECOG performance status \<3; * written informed consent. Exclusion Criteria: * Inflammatory breast cancer or skin involvement; * previous breast cancer surgery or radiotherapy to the affected breast; * BMI \>35 kg/m²; active smoking; ASA Physical Status \>2; * pregnancy or breastfeeding; * inability to provide informed consent; * participation in incompatible interventional clinical trials.
Conditions Metastatic Breast Cancer
Phase PHASE1
Enrollment 69
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1\*).

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells — huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
  • Biological: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D — huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D

Primary Outcomes

  • Incidence of Adverse Events (Within 35 days after T cell infusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2020-01-15
Completion: 2035-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 69 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Minerva Biotechnologies Corporation
Collaborators: City of Hope Medical Center
Principal Investigators:
  • Joanne Mortimer, MD (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Joanne Mortimer, MD
1-800-826-4673
Minerva18625@coh.org
Joanne Mortimer, MD
800-826-4673
City of Hope Medical Center
Joanne Mortimer, MD
City of Hope Medical Center
Interventions
  • Biological: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells — huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
  • Biological: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D — huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
Study Locations (1 sites)
City of Hope Medical Center, Duarte, California 91010-3000 United States
Eligibility Criteria
Please note that results of tests and/or procedures conducted as per standard of care purposes may be used for research purposes if conducted within the protocol-defined window prior to screening/leukapheresis and/or T-Cell Therapy. Inclusion Criteria: 1. Confirmation of diagnosis of breast cancer by pathology review of initial or subsequent biopsy or other pathologic material at the City of Hope Pathology department. ER, PR, and HER2 status known and documented per ASCO/CAP guidelines. 1. For dose expansion cohorts, tumors with ER and/or PR ≥1% will be considered hormone receptor positive. Tumors with ER and PR \<1% will be considered hormone receptor negative. HER2 status will be determined by IHC or FISH per ASCO/CAP guidelines. Patients will be allocated to expansion cohorts according to guidelines in table below. 2. Dose expansion cohorts Expansion Cohort Hormone Receptor status HER2 status Luminal ER and/or PR \>/=1% positive Negative by IHC or FISH HER2 positive Any ER or PR status Positive by IHC or FISH Triple Negative ER and PR \<1% Negative by IHC or FISH 2. Patients must have received standard metastatic systemic therapy per NCCN guidelines or institutional practice which are known to confer benefit. No maximum on number of prior systemic treatment regimens. 1. Patients with hormone receptor positive disease must have received at least 3 prior endocrine therapies and at least 2 prior lines of chemotherapy in the metastatic setting. 2. Patients with HER2 positive breast cancer must have received at least 3 prior HER2- directed therapies (trastuzumab, pertuzumab, TDM-1 or others) in the metastatic setting. 3. Patients with triple negative disease must have received at least 2 prior lines of chemotherapy in the metastatic setting. 3. MUC1\* membrane expression ≥30% by immunohistochemistry on a tumor specimen obtained at screening or previous tumor specimen that is less than 6-months old (see Appendix I for examples of MUC1\* expression patterns). 4. Patients must be 18 years of age or older, of any gender, race or ethnicity. 5. Patients must be capable of understanding and providing a written informed consent. 6. Patients must have a Karnofsky performance status of ≥60%. 7. Patients must have measurable disease by at least one of the criteria below: 1. Extra skeletal disease that can be accurately measured by CT or MRI per RECIST 1.1, 2. Skeletal or bone-only metastases measurable by FDG PET imaging. 8. Negative serum pregnancy test within 14 days of planned leukapheresis and within 28 days of lymphodepleting chemotherapy for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year. 9. Fertile male and female patients must be willing to use an effective contraceptive method before, during, and for at least 4 months after the huMNC2-CAR T cell infusion. Exclusion Criteria: 1. Patients requiring ongoing daily corticosteroid therapy at a dose of \>15 mg of prednisone per day (or equivalent). Pulsed corticosteroid use for disease control is acceptable. 2. Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the PI. 3. Major organ dysfunction defined as: 1. Serum creatinine \> 2 mg/dL 2. Bilirubin ≥ 1.5 mg/dL with the following exception: Patients with known Gilbert disease, serum bilirubin \> 3 mg/dL 3. AST or ALT ≥ 2.5 x upper institutional limit of normal with the following exception: Patients with known hepatic metastases, AST or ALT \> 3x upper institutional limit of normal 4. Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing. Those with an FEV1 of \< 50 % of predicted or DLCO (corrected) \< 40% will be excluded. 5. Significant cardiovascular abnormalities as defined by any one of the following: i. NYHA class III or IV congestive heart failure, ii. clinically significant hypotension, iii. uncontrolled symptomatic coronary artery disease, or iv. a documented ejection fraction of \<45%. Any patient with an EF of 45-49% must receive clearance by a cardiologist to be eligible for the trial. 4. ANC \<1000/mm\^3. 5. Hemoglobin \<9 mg/dl (transfusion permitted to achieve this). 6. Platelet count \<75,000/mm\^3. 7. Treatment with investigational agent(s) within 30 days of planned lymphodepletion. 8. HIV seropositive. 9. Uncontrolled active infection. 10. Anticipated survival of \<3 months. 11. Breast-feeding women. 12. Patients who have a contraindication to cyclophosphamide chemotherapy. 13. Known second malignancy that is progressing or requires active treatment. 14. Untreated CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate with documented stable disease as defined by no evidence of progression by imaging or symptoms for at least 4 weeks prior to enrollment. 15. Have psychiatric illness, social situation, or other medical condition that would preclude informed consent to limit compliance with study requirements, as determined by the investigator.
Conditions Breast Cancer, Cognitive Impairment
Phase NA
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate whether a high definition tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in women with post-chemotherapy cognitive impairment after breast cancer treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Anodal tDCS — Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
  • Device: Sham tDCS — Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
  • Behavioral: Intensive cognitive training — Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min

Primary Outcomes

  • Working memory performance at post-assessment (3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-02
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medicine Greifswald
Collaborators: University of Greifswald
Principal Investigators:
  • Agnes Flöel, Prof. (STUDY_DIRECTOR) - University Medicine Greifswald
Contact Information
Study Contact:
Agnes Flöel, Prof.
0049 3834 86 6815
agnes.floeel@med.uni-greifswald.de
Daria Antonenko, Dr.
0049 3834 86 6754
daria.antonenko@med.uni-greifswald.de
Agnes Flöel, Prof.
0049 3834 86 6815
agnes.floeel@med.uni-greifswald.de
University Medicine Greifswald
Interventions
  • Device: Anodal tDCS — Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
  • Device: Sham tDCS — Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
  • Behavioral: Intensive cognitive training — Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
Study Locations (1 sites)
University Medicine Greifswald, Greifswald, Germany
Eligibility Criteria
Inclusion Criteria: 1. Chemotherapy to treat breast cancer (≥ 6 months post-treatment). 2. Self-reported concerns regarding cognitive functioning. 3. Age: 18-65 years. 4. right-handedness Exclusion Criteria: 1. History of dementia before treatment of cancer. 2. Other neurodegenerative neurological disorders; epilepsy or history of seizures. 3. Severe and untreated medical conditions that preclude participation in the training, as determined by responsible physician. 4. History of moderate to severe substance use disorder according to DSM-5 5. Moderate to severe acute psychiatric disorders according to DSM-5 6. Contraindication to tDCS application (Antal et al., 2017)
Conditions HR Positive HER2 Negative Advanced Breas...
Phase PHASE2
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, open-label, randomized, multicenter, two-cohort phase II clinical trial. Starting from December 1, 2024, it plans to enroll 120 patients with advanced first-line HR-positive, HER2-negative breast cancer. A centralized randomization system (IWRS) will be used for randomization, and stratification will be performed based on the following factors during randomization: 1) Visceral metastasis (yes vs no); 2) Disease-free interval (previously untreated vs 12 \< DFI ≤ 24 vs DFI \> 24). Cohort A: Dalpiciclib 125mg + Letrozole 2.5mg Cohort B: Dalpiciclib 150mg + Letrozole 2.5mg Imaging assessment will be conducted in accordance with the RECIST 1.1 criteria, and tumor imaging evaluation will be performed by investigators from the participating centers. Patients receiving dalpiciclib will undergo a safety visit 28 days after the last dose, followed by survival follow-up until the patient's death or trial termination (whichever comes first). Pharmacokinetic assessment: Blood samples will be collected once before dosing on Cycle 1 Day 15 (C1D15), 4 hours after dosing on C1D15, before dosing on Cycle 2 Day 1 (C2D1), and before dosing on Cycle 4 Day 1 (C4D1) to explore the population pharmacokinetic characteristics of dalpiciclib and the factors affecting its pharmacokinetics. The first dosing time of the subjects, each blood collection time, the dalpiciclib dosing time within three days before blood collection, and the dalpiciclib dosing time on the day of C1D15 blood collection must be accurately recorded. If dalpiciclib is not administered within 14 days before the planned PK blood collection, no PK blood collection will be performed on the day of that visit. If possible, PK samples should be collected simultaneously with samples for other laboratory tests.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalpiciclib 125mg — Oral administration, 125mg,Dalpiciclib is administered for 3 weeks, followed by 1 week of rest
  • Drug: Dalpiciclib 150mg — Oral administration, 150mg,Dalpiciclib is administered for 3 weeks, followed by 1 week of rest
  • Drug: Letrozole 2.5mg — Oral administration, 2.5mg, administered once daily until disease progression or unacceptable toxicity

Primary Outcomes

  • Progression - Free Survival (PFS) (From date of randomization until the date of first documented disease progression or death from any cause (whichever comes first), assessed per RECIST 1.1 criteria up to 104 weeks)
  • Duration of Response (DoR) (From the date of first documented complete response (CR) or partial response (PR) (per RECIST 1.1, assessed by investigators via imaging) until the date of first documented disease progression (per RECIST 1.1) or recurrence, assessed up to 104 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-25
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: wanghaibo
Contact Information
Study Contact:
haibo Wang
18661805787
hbwang66@126.com
man Li
17709873580
dmuliman@163.com
The Second Affiliated Hospital of Dalian Medical University
haibo Wang
18661805787
hbwang66@126.com
Qingdao University Affiliated Hospital
Interventions
  • Drug: Dalpiciclib 125mg — Oral administration, 125mg,Dalpiciclib is administered for 3 weeks, followed by 1 week of rest
  • Drug: Dalpiciclib 150mg — Oral administration, 150mg,Dalpiciclib is administered for 3 weeks, followed by 1 week of rest
  • Drug: Letrozole 2.5mg — Oral administration, 2.5mg, administered once daily until disease progression or unacceptable toxicity
Study Locations (2 sites)
The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027 China
Qingdao University Affiliated Hospital, Qingdao, Shandong 266000 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥18 years and ≤75 years, who are postmenopausal or premenopausal/perimenopausal, and meet one of the following conditions: 1. Have undergone bilateral oophorectomy in the past, or be aged ≥60 years; or 2. Aged \<60 years, in a natural postmenopausal state (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without other pathological or physiological causes), with E2 and FSH at postmenopausal levels; or 3. Premenopausal or perimenopausal female patients can also be enrolled, but must be willing to receive LHRH agonist treatment during the study period * Patients with breast cancer confirmed by pathological examination to be HR-positive and HER2-negative, with evidence of focal recurrence or metastasis, not suitable for surgical resection or radiotherapy with the goal of cure, and without clinical indications for chemotherapy. 1. ER-positive and/or PR-positive is defined as: the proportion of tumor cells with positive staining among all tumor cells is ≥1% (reviewed and confirmed by the investigator at the participating trial center); 2. HER2-negative is defined as: standard immunohistochemistry (IHC) test result is 0/1+; ISH test shows that the HER2/CEP17 ratio is less than 2.0 or the HER2 gene copy number is less than 4 (reviewed and confirmed by the investigator at the participating trial center) * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 * Have not previously received any systemic antineoplastic treatment for focal recurrent or metastatic disease * Have measurable lesions in line with RECIST 1.1 criteria or only bone metastatic lesions (including osteolytic lesions or mixed osteolytic/osteoblastic lesions) * Have sufficient organ and bone marrow function * Women of childbearing potential must be willing to use a medically approved highly effective contraceptive method during the study period and within 3 months after the last administration of the study drug * All acute toxic effects of previous antineoplastic treatment have resolved to grade 0-1 (according to NCI-CTCAE Version 5.0) or to the level specified in the inclusion/exclusion criteria. Except for other toxicities such as alopecia that the investigator deems to pose no safety risk to the patient * Have given informed consent and signed the informed consent form, and be willing and able to comply with the planned visits, study treatment plan, laboratory tests and other trial procedures Exclusion Criteria: * Previously diagnosed with HER2-positive breast cancer by pathological examination * Inflammatory breast cancer * Disease progression or recurrence at 12 months or within 12 months after completion of previous neoadjuvant or adjuvant endocrine drug treatment * Patients judged by the investigator to be unsuitable for endocrine treatment. Including advanced patients with symptoms, disseminated to internal organs, and at risk of life-threatening complications in the short term (including those with uncontrollable large effusions \[pleural, pericardial, peritoneal\], lymphangitis of the lung, and patients with more than 50% liver involvement) Confirmed to have brain metastatic lesions by cranial CT or MRI examination * Have previously received any CDK4/6 inhibitor drug treatment * Underwent major surgery, chemotherapy, radiotherapy, any investigational drug or other anticancer treatment within 2 weeks before entering the study Diagnosed with any other malignant tumor within 3 years before entering the study, except for non-melanoma skin cancer, basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix that have undergone radical treatment Human Immunodeficiency Virus (HIV) infection or known to have Acquired Immunodeficiency Syndrome (AIDS), active hepatitis B (HBV DNA ≥1000 IU/ml), hepatitis C (positive hepatitis C antibody and HCV-RNA higher than the lower limit of detection of the analytical method), or co-infection with hepatitis B and hepatitis C * Within 6 months before entering the study, the following occurred: myocardial infarction, severe/unstable angina pectoris, NYHA class 2 or higher cardiac insufficiency, persistent arrhythmia of grade ≥2 (according to NCI-CTCAE Version 5.0), atrial fibrillation of any grade, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism) * Complicated with severe infection within 4 weeks before the first administration (e.g., requiring intravenous infusion of antibiotics, antifungal or antiviral drugs according to clinical diagnosis and treatment norms), or unexplained fever \>38.5℃ during the screening period/before the first administration * Inability to swallow, intestinal obstruction, or other factors that affect drug administration and absorption * Known allergy to the study drug or any excipients * Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation * Known history of psychiatric drug abuse or drug addiction * Patients currently participating in other studies * Have other serious physical or mental diseases or laboratory test abnormalities that may increase the risk of participating in the study, interfere with the study results, and are deemed unsuitable for participating in this study by the investigator
Conditions Breast Cancer, Residual Disease, Triple ...
Phase PHASE2
Enrollment 78
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (MRD) detection to enable real-time measurement with clinical-grade assays. The primary objective of this study will be to evaluate ctDNA-based MRD status in high-risk, early-stage TNBC patients by defining the proportion of TNBC patients with MRD-only recurrence (ctDNA positive without radiographically measurable recurrence) during post-surgery surveillance. The secondary objectives will evaluate the safety, preliminary efficacy, and survival outcomes of using Dato-DXd in participants with MRD-only TNBC. Dato-DXd is an investigational antibody-drug conjugate (monoclonal antibody specific for TROP2 and a topoisomerase I (Topo-1) inhibitor) that has demonstrated promising efficacy in TNBC patients with a manageable safety profile.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Datopotamab deruxtecan — Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.
  • Diagnostic Test: Circulating tumor DNA (ctDNA) testing — Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.

Primary Outcomes

  • The proportion of triple negative breast cancer (TNBC) with molecular residual disease (MRD) (Up to 3 years after registration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-26
Completion: 2032-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: AstraZeneca, Translational Breast Cancer Research Consortium
Principal Investigators:
  • Yara Abdou, MD (PRINCIPAL_INVESTIGATOR) - UNC Lineberger Comprehensive Cancer Center
Contact Information
Study Contact:
Taylor Pierce
(919) 445-4827
Taylor_Pierce@med.unc.edu
Ana Gallegos
919-445-4827
ana_gallegos@med.unc.edu
UNC Lineberger Comprehensive Cancer Center
Taylor Pierce
(919) 445-4827
tepierce@email.unc.edu
UNC Lineberger Comprehensive Cancer Center
Interventions
  • Drug: Datopotamab deruxtecan — Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.
  • Diagnostic Test: Circulating tumor DNA (ctDNA) testing — Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.
Study Locations (1 sites)
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27514 United States
Eligibility Criteria
Inclusion Criteria: Written informed consent was obtained to participate in the study, and HIPAA authorization for the release of personal health information. * Participant is willing and able to comply with study procedures based on the judgment of the investigator. * Age ≥ 18 years at the time of consent. * Histological confirmation of TNBC defined by ER/PR \<10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative. * Stage II/III TNBC treated with neoadjuvant systemic therapy AND have residual disease defined as RCB II/III at time of surgery. * Baseline staging scans at the discretion of the treating physician and demonstrate no evidence of metastatic disease. * The participant must have archival diagnostic tissue and/or surgical resection tissue Available. * Participants are willing and able to comply with study procedures based on the judgment of the investigator. Exclusion Criteria: • Participants are pregnant or breastfeeding.
Conditions Breast Cancer, BRCA 1 Gene Mutation, BRC...
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to learn whether a handheld robotic device, called the HandX, can help surgeons safely perform a minimally invasive nipple-sparing mastectomy. This type of mastectomy uses a small incision at the side of the breast to remove breast tissue while keeping the skin and nipple in place. The goal is to lower scarring, improve comfort, and support good cosmetic results after surgery. Participants in this study will already be planning to have a therapeutic or preventive mastectomy with immediate implant-based reconstruction. All surgeries are done at Mediterraneo Hospital in Greece. During the operation, surgeons use the HandX device to assist with the endoscopic dissection. Researchers will collect information about how long the surgery takes, whether the planned approach can be completed without switching to open surgery, and whether any surgical complications occur. They will also check healing, infection, and implant-related problems for up to 365 days after surgery. Participants will complete the BREAST-Q questionnaire before surgery and at several times after surgery to share their views on comfort, well-being, and cosmetic outcomes. About 15 participants will take part. The results will help researchers understand whether this approach is practical and safe, and whether it should be studied further in a larger trial.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic nipple sparing mastectomy — A minimally invasive nipple-sparing mastectomy performed through a single lateral mammary fold incision using endoscopic visualization and CO₂ insufflation. Breast tissue is dissected from the skin envelope and nipple-areola complex, and immediate implant-based reconstruction is performed according to standard practice. The HandX device is used for articulating endoscopic dissection.
  • Device: HandX endoscopic instrument — A handheld articulating endoscopic instrument used to assist with endoscopic dissection during nipple-sparing mastectomy. The HandX device provides wrist-like articulation, motion scaling, and ergonomic control during minimally invasive surgery.

Primary Outcomes

  • Technical success (Intraoperative (Day 0))
  • Surgical Safety (Postoperative Day 0-30)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-09
Completion: 2029-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vasileios Kalles
Principal Investigators:
  • Vasileios Kalles, MD, MSc, PhD, FEBS (PRINCIPAL_INVESTIGATOR) - Mediterraneo Hospital
Contact Information
Study Contact:
Vasileios Kalles, MD, MSc, PhD, FEBS
00306973746477
vassilis_kalles@yahoo.gr
Vasileios Kalles, MD, MSc, PhD, FEBS
00306973746477
vassilis_kalles@yahoo.gr
Mediterraneo Hospital
Ioannis Papapanagiotou, MD, MSc, PhD
Mediterraneo Hospital
Interventions
  • Procedure: Endoscopic nipple sparing mastectomy — A minimally invasive nipple-sparing mastectomy performed through a single lateral mammary fold incision using endoscopic visualization and CO₂ insufflation. Breast tissue is dissected from the skin envelope and nipple-areola complex, and immediate implant-based reconstruction is performed according to standard practice. The HandX device is used for articulating endoscopic dissection.
  • Device: HandX endoscopic instrument — A handheld articulating endoscopic instrument used to assist with endoscopic dissection during nipple-sparing mastectomy. The HandX device provides wrist-like articulation, motion scaling, and ergonomic control during minimally invasive surgery.
Study Locations (1 sites)
Mediterraneo Hospital, Glyfada, Attica 16675 Greece
Eligibility Criteria
Inclusion Criteria: * Female sex * Age ≥ 18 years old * Indication for therapeutic or prophylactic (risk-reducing) mastectomy for: 1. early invasive breast cancer (Clinical Stage I-II at diagnosis) undergoing primary surgery 2. early invasive breast cancer (Clinical Stage I-II at diagnosis) undergoing surgery post systemic (neoadjuvant) therapy with clinical evidence of partial or complete response 3. ductal carcinoma in situ (DCIS), or 4. BRCA or other breast cancer - related genetic mutation carriers, or 5. high risk for development of breast cancer. * Breast volume: cup sizes A to C as defined by underwear size, expected implant volume \<550cc and glandular ptosis not exceeding Grade I Regnault's classification. * ECOG / WHO Performance Status \<2 * Subject with signed and dated informed consent form Exclusion Criteria: * Chest wall or skin invasion * Extended lymph node involvement at diagnosis (cN2) * Inflammatory breast cancer * Tumor distance from nipple - areola complex \<1cm on imaging studies * Active smoking/nicotine use within 4 weeks pre-op (combustible tobacco, vaping, nicotine pouches, NRT) * BMI \>35 * High risk patients with severe and poorly controlled co-morbid conditions (including but not limited to diabetes, heart disease, renal failure or liver dysfunction) * Pregnancy or breastfeeding * Psychiatric, addictive, or any disorders which compromise the ability to give informed consent for participation in this study * Subject without signed and dated informed consent form
Conditions Lobular Breast Carcinoma
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative/low invasive lobular carcinoma of the breast. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Procedure: Upfront Breast Surgery — Upfront Conservative or Demolitive Breast Surgery
  • Radiation: Adjuvant Radiotherapy — Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
  • Drug: Endocrine Therapy — Adjuvant or Neoadjuvant Endocrine Therapy
  • Drug: Chemotherapy — Adjuvant or Neoadjuvant Chemotherapy

Primary Outcomes

  • Invasive disease-free survival (iDFS) (Through study completion, an average of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Oncologico Veneto IRCCS
Principal Investigators:
  • Francesco Milardi, MD (STUDY_CHAIR) - Veneto Institute of Oncology IRCCS
Contact Information
Study Contact:
Massimo Ferrucci, MD PhD
049 821 5500
massimoferrucci@gmail.com
Daniele Passeri, MD
+39 333 383 9397
daniele.passeri.1995@gmail.com
Massimo Ferrucci, MD PhD
049 821 5500
massimoferrucci@gmail.com
Veneto Institute of Oncology
Interventions
  • Procedure: Upfront Breast Surgery — Upfront Conservative or Demolitive Breast Surgery
  • Radiation: Adjuvant Radiotherapy — Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
  • Drug: Endocrine Therapy — Adjuvant or Neoadjuvant Endocrine Therapy
  • Drug: Chemotherapy — Adjuvant or Neoadjuvant Chemotherapy
Study Locations (1 sites)
Veneto Institute of Oncology, Padova, Italy
Eligibility Criteria
Inclusion Criteria: * Female or male patients aged ≥18 years; * Histologically confirmed ILC, confirmed by E-cadherin loss/aberrant expression and/or p120 cytoplasmic relocalization and/or CDH1 alteration; * HR-negative (ER \<1% and PR \<1%) or HR-low (ER and/or PR 1-10%) disease, as defined by ASCO/CAP guidelines, is eligible regardless of HER2 status (assessed according to 2025 ASCO/CAP criteria, with HER2-low and HER2-ultralow status recorded where assessable); * HR-positive (ER\>10% according to the ASCO/CAP guidelines) ILC is eligible only if HER2 status is positive; * Mixed ductal-lobular carcinomas are eligible provided that a clearly identified invasive lobular component is present and predominant (\>50% lobular) and HR-negative/low criteria are met; * Stage I-III disease at diagnosis; Patients with de novo stage IV disease who underwent surgery of the primary tumor will not be included in the main study cohort but may be captured in a separate exploratory cohort for dedicated analysis; * Patients who underwent surgery of the primary tumor at the participating institution, either upfront or after neoadjuvant systemic treatment; * Diagnosis occurred between 1 January 2000 and 31 December 2025; * Minimum follow-up of 12 months for patients without an event, unless recurrence or death occurred earlier; * Local review by a dedicated breast pathologist to confirm the diagnosis and the related molecular features, with particular attention to the confirmation of apocrine morphology. Exclusion Criteria: * Pure IC NST without any lobular invasive component; * ER or PR expression \>10% in the invasive component, in cases with negative HER2 status; * In situ lobular neoplasia (lobular carcinoma in situ) without an invasive component; * De novo stage IV disease (such patients, if they underwent surgery of the primary tumor, will be captured in a separate exploratory cohort for a dedicated analysis) * Synchronous invasive BC of another dominant histology requiring systemic treatment that precludes attribution of outcomes to HR-negative/low ILC; * Prior invasive BC under active systemic treatment at the time of diagnosis, unless clearly documented as unrelated and not expected to confound outcomes; * Insufficient data or follow up
Conditions Hormone Receptor Positive Breast Carcino...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Tai Chi — Routine virtual Tai Chi group classes via Zoom for 1 hour, twice a week, for 12 weeks, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow-up.
  • Behavioral: Health Education — Routine virtual AC classes delivered remotely, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow up.

Primary Outcomes

  • Consent Rate (Up to 6 months)
  • Engagement Rate (12 weeks)
  • Retention Rate (20 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-27
Completion: 2029-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Principal Investigators:
  • Kuang-Yi Wen, PhD (PRINCIPAL_INVESTIGATOR) - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Contact Information
Study Contact:
Kuang-Yi Wen, PhD
215-503-4623
Kuang-Yi.Wen@Jefferson.edu
Kuang-Yi Wen, MD
2155034623
Kuang-Yi.Wen@Jefferson.edu
Sidney Kimmel Cancer Center at Thomas Jefferson University
Interventions
  • Behavioral: Tai Chi — Routine virtual Tai Chi group classes via Zoom for 1 hour, twice a week, for 12 weeks, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow-up.
  • Behavioral: Health Education — Routine virtual AC classes delivered remotely, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow up.
Study Locations (1 sites)
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: -Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study: * Age ≥18 years * Diagnosis of stage I-III hormone receptor-positive breast cancer * Postmenopausal * Currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation * Report joint pain that started or worsened after initiation of AI therapy * Report worst pain in the past week ≥3 on the BPI (0-10 scale) * Able to complete study procedures in English * Willing to be randomized to an intervention or attention control group and adhere to study procedures Exclusion Criteria: -An individual who meets any of the following criteria will be excluded from participation in this study: * Undergoing active cancer treatment (excluding endocrine therapy) * Uncontrolled cardiac or pulmonary disease that would limit safe participation * Currently engaged in regular structured moderate- or vigorous-intensity exercise (e.g., brisk walking, jogging/running, cycling, swimming, aerobic classes, or resistance training) totaling ≥150 minutes per week over the past 3 months * Currently participating in Tai Chi, yoga, Pilates, or other structured mind-body practice ≥2 times per week over the past 3 months * Joint pain due to inflammatory arthritic conditions * Recent surgery or joint injection within the past 4-6 weeks * Initiation or dose change of corticosteroids or opioids within the past 4 weeks * Planned discontinuation of AI therapy within the next 6 months * This study is limited to women with breast cancer, as \<1% of cases occur in men and data on AIIA in male patients are limited
Conditions Breast Cancer
Phase NA
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to assess the rates of circulating tumour DNA (ctDNA) in patients treated with surgery for stage 1 breast cancer that is HER2 positive or triple negative. The study will involve collecting blood samples from patients before and after surgery, if patients are enrolled after surgery, blood samples will be collected after the procedure. On the follow-up visit, the results obtained from the blood tests will serve as a diagnostic method to discern adverse outcomes in the groups of patients with positive and negative ctDNA detection. Also, the results obtained will aid physicians in determining treatment courses for patients, in order to reduce the intensity of adjuvant chemotherapy. By identifying the patients with residual disease with ctDNA analysis, it is possible that this will improve disease prognosis.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: ctDNA — Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.

Primary Outcomes

  • Incidence of patients with ctDNA detection treated with surgery for stage 1 breast cancer (2 to 4 weeks post surgery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-05
Completion: 2028-12-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: Massachusetts General Hospital, Natera, Inc.
Principal Investigators:
  • Nicholas Turner (PRINCIPAL_INVESTIGATOR) - Royal Marsden NHS Foundation Trust
Contact Information
Study Contact:
Project Manager
020 7808 2887
SAFE-DE@rmh.nhs.uk
Trial Manager
020 7808 2887
SAFE-DE@rmh.nhs.uk
The Royal Marsden NHS Foundation Trust, Chelsea
Trial Manager
02078082887
safe-de@rmh.nhs.uk
The Royal Marsden NHS Foundation Trust, Sutton
Interventions
  • Diagnostic Test: ctDNA — Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
Study Locations (2 sites)
The Royal Marsden NHS Foundation Trust, Chelsea, London, SW3 6JJ United Kingdom
The Royal Marsden NHS Foundation Trust, Sutton, Sutton, SM5 5PT United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older. 2. Patients with histologically confirmed breast cancer that is either A) HER2 positive as defined by 2018 ASCO-CAP guidelines determined by local testing B) Triple negative defined as ER negative (ER staining in \<1% tumour cells or ER Allred score \<3/8) and PR negative (PR staining in \<10% tumour cells or PR Allred score \<6/8) and HER2 negative by 2018 ASCO-CAP guidelines determined by local testing. Patients without PR testing results may enrol on the basis of ER and HER2 results. Note that patients negative for ER and PR may enrol whilst awaiting HER2 testing results 3. Stage 1 cancer excluding pT1aN0 cancer, defined as A) Patients prior to surgery with primary tumour size on imaging 6-20mm and a normal axilla ultrasound or a biopsy negative axilla Patients who enrol prior to surgery will only continue further testing in the trial if their pathological staging fits the after surgery criteria. B) Patients after surgery with either * Primary tumour size pT1b or pT1c (6-20mm) and pN0 or pN1mi (micrometastasis). * Primary tumour size pT1a (1-5mm) and pN1mi Note that patients consenting after surgery may not enrol with pT1aN0 stage disease 4. Patients should consent prior to surgery (preferred) or within 2 weeks of surgery. Patients who consent after surgery may extend consent to 4 weeks after surgery, although this will delay the receipt of ctDNA results. 5. Planned and fit enough to receive full standard post-operative chemotherapy, with HER2 targeting as appropriate. 6. Ability to give informed consent and comply with study procedures including blood tests and follow-up for five years. Exclusion Criteria: 1. Distant metastatic disease. 2. Multifocal invasive cancer 3. Diagnosis of alternative cancer within the last 5 years other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia. 4. Any prior treatment (including neo-adjuvant chemotherapy) for the current breast cancer with the exception of surgical resection for patients enrolling after surgery. 5. Known HIV or hepatitis B or hepatitis C infection.